JP2020516240A5 - - Google Patents

Info

Publication number

JP2020516240A5

JP2020516240A5 JP2019553886A JP2019553886A JP2020516240A5 JP 2020516240 A5 JP2020516240 A5 JP 2020516240A5 JP 2019553886 A JP2019553886 A JP 2019553886A JP 2019553886 A JP2019553886 A JP 2019553886A JP 2020516240 A5 JP2020516240 A5 JP 2020516240A5

Authority

JP

Japan

Prior art keywords

antibody

amino acid

seq

acid sequence

human

Prior art date

2018-04-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims 54
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 44
• 102000050327 human TNFRSF9 Human genes 0.000 claims 32
• 229910052739 hydrogen Inorganic materials 0.000 claims 18
• 230000000694 effects Effects 0.000 claims 13
• 239000005557 antagonist Substances 0.000 claims 11
• 210000004027 cell Anatomy 0.000 claims 10
• 102000040430 polynucleotide Human genes 0.000 claims 10
• 108091033319 polynucleotide Proteins 0.000 claims 10
• 239000002157 polynucleotide Substances 0.000 claims 10
• 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 9
• 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 9
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
• 239000001257 hydrogen Substances 0.000 claims 7
• 102000004169 proteins and genes Human genes 0.000 claims 7
• 108090000623 proteins and genes Proteins 0.000 claims 7
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 6
• 229910052805 deuterium Inorganic materials 0.000 claims 6
• 239000003814 drug Substances 0.000 claims 6
• 229940124597 therapeutic agent Drugs 0.000 claims 6
• 206010028980 Neoplasm Diseases 0.000 claims 5
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 4
• 102000002812 Heat-Shock Proteins Human genes 0.000 claims 4
• 108010004889 Heat-Shock Proteins Proteins 0.000 claims 4
• ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 4
• ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims 4
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 4
• 230000035772 mutation Effects 0.000 claims 4
• 239000008194 pharmaceutical composition Substances 0.000 claims 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims 4
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
• 230000003213 activating effect Effects 0.000 claims 3
• 238000004132 cross linking Methods 0.000 claims 3
• 239000012634 fragment Substances 0.000 claims 3
• -1 host cell Substances 0.000 claims 3
• 230000001965 increasing effect Effects 0.000 claims 3
• 238000000034 method Methods 0.000 claims 3
• 150000001413 amino acids Chemical class 0.000 claims 2
• 239000000427 antigen Substances 0.000 claims 2
• 210000000612 antigen-presenting cell Anatomy 0.000 claims 2
• 108091007433 antigens Proteins 0.000 claims 2
• 102000036639 antigens Human genes 0.000 claims 2
• 238000003556 assay Methods 0.000 claims 2
• 239000003795 chemical substances by application Substances 0.000 claims 2
• 229940127089 cytotoxic agent Drugs 0.000 claims 2
• 238000006471 dimerization reaction Methods 0.000 claims 2
• 210000004602 germ cell Anatomy 0.000 claims 2
• 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 2
• 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 2
• 239000003112 inhibitor Substances 0.000 claims 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
• 230000008685 targeting Effects 0.000 claims 2
• 229960005486 vaccine Drugs 0.000 claims 2
• YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 claims 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
• 208000035473 Communicable disease Diseases 0.000 claims 1
• 101100451497 Dictyostelium discoideum hspB gene Proteins 0.000 claims 1
• 108010021472 Fc gamma receptor IIB Proteins 0.000 claims 1
• 101150022862 HSC70 gene Proteins 0.000 claims 1
• 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
• 101001005365 Homo sapiens Immunoglobulin lambda variable 3-21 Proteins 0.000 claims 1
• 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
• 102100025934 Immunoglobulin lambda variable 3-21 Human genes 0.000 claims 1
• 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims 1
• YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 claims 1
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
• 210000001744 T-lymphocyte Anatomy 0.000 claims 1
• 239000000556 agonist Substances 0.000 claims 1
• 230000003042 antagnostic effect Effects 0.000 claims 1
• 230000000890 antigenic effect Effects 0.000 claims 1
• 239000002246 antineoplastic agent Substances 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 230000032823 cell division Effects 0.000 claims 1
• 230000002596 correlated effect Effects 0.000 claims 1
• 230000008878 coupling Effects 0.000 claims 1
• 238000010168 coupling process Methods 0.000 claims 1
• 238000005859 coupling reaction Methods 0.000 claims 1
• 239000002254 cytotoxic agent Substances 0.000 claims 1
• 231100000599 cytotoxic agent Toxicity 0.000 claims 1
• 231100000655 enterotoxin Toxicity 0.000 claims 1
• 229950006370 epacadostat Drugs 0.000 claims 1
• 230000028993 immune response Effects 0.000 claims 1
• 230000001939 inductive effect Effects 0.000 claims 1
• 230000004941 influx Effects 0.000 claims 1
• 230000004073 interleukin-2 production Effects 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 210000001165 lymph node Anatomy 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 229960003301 nivolumab Drugs 0.000 claims 1
• 229960002621 pembrolizumab Drugs 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 238000007910 systemic administration Methods 0.000 claims 1
• 231100000765 toxin Toxicity 0.000 claims 1
• 239000003053 toxin Substances 0.000 claims 1
• 108700012359 toxins Proteins 0.000 claims 1